Regulatory glossary

OTC Monograph: Marketing a Nonprescription Drug Without an NDA

An OTC monograph is a regulation setting the conditions under which a nonprescription drug in a therapeutic category is generally recognised as safe and effective, or GRASE. It fixes the permitted active ingredients, doses, indications, routes, labelling and testing.

The consequence is the point. A product that conforms to its monograph can be marketed without FDA reviewing or approving it individually. There is no application and no approval letter. You conform, and you ship.

Two routes to market

The monograph route. Your product matches an existing monograph: the active ingredient, at a permitted concentration, for a listed indication, with the required labelling. Most OTC products go this way, because there are no user fees for the product itself and no premarket review to wait for.

The application route. A new active ingredient, a new dose, a new indication, a new route, anything outside the monograph. That needs an NDA, or more often a 505(b)(2) relying in part on published literature or a previous finding of safety and effectiveness. FDA typically requires consumer studies showing people can select and use the product correctly without a clinician.

Deciding which route you are on is the first regulatory question, and it is answered by reading the monograph, not by judging how familiar the product seems.

What the CARES Act changed

The monograph system began with the 1972 OTC Drug Review, covering 36 therapeutic categories, and ran on notice-and-comment rulemaking. Rulemaking is slow, and categories sat unfinished for decades in "tentative final monograph" status.

The CARES Act in 2020 replaced rulemaking with an administrative order process. In practice:

• Existing monographs and tentative final monographs were deemed final orders, so the long-unfinished categories became enforceable.
• FDA or industry can now initiate a change by administrative order. Industry does so with an OTC Monograph Order Request (OMOR).
• User fees arrived, under OMUFA, including facility fees for OTC monograph drug facilities and fees on order requests.

If your regulatory knowledge of this area predates 2020, the mechanism you learned no longer exists.

What conformity still requires

Not needing approval is not the same as being unregulated. A monograph product still requires:

• Establishment registration and drug listing, with an NDC.
• CGMP compliance under 21 CFR 210 and 211, which is what most OTC warning letters are actually about.
• Drug Facts labelling in the prescribed format and order.
• Adverse event reporting for serious events, under the Dietary Supplement and Nonprescription Drug Consumer Protection Act.

The common failure is a contract manufacturer producing a conforming formula in a facility that cannot pass a CGMP inspection. The formula was never the risk.